Repare Therapeutics Inc. — Cyborg Score 5/10

Strategic Profile

As of January 16, 2026, Repare shareholders approved a plan of arrangement to be acquired by XenoTherapeutics with 99.76% of votes cast in favor. The company has monetized its portfolio through major licensing deals, including a worldwide agreement with Debiopharm for lunresertib worth up to $257 million in milestones, and out-licensed its discovery platforms to DCx Biotherapeutics receiving $1 million upfront and a 9.99% equity stake.

Cyborg Score Rationale

The company ended Q1 2025 with $124.2 million in cash expected to fund operations through 2027. However, the company faces execution risk as a clinical-stage biotech with multiple Phase 1/2 programs and is undergoing acquisition by a non-profit entity, creating strategic uncertainty.

Top Insights

• Pipeline includes multiple clinical programs: RP-1664 (Phase 1 PLK4 inhibitor), RP-3467 (Polθ inhibitor), camonsertib/RP-3500 (ATR inhibitor Phase 1/2), and lunresertib/RP-6306 (PKMYT1 inhibitor Phase 1/2).
• Major deal with Debiopharm for lunresertib represents $257M+ in potential milestone payments plus royalties.
• XenoTherapeutics acquisition approved by 99.76% shareholder vote, representing significant strategic pivot toward non-profit research model.
• As of January 28, 2026, Repare operates as a subsidiary of Xenotherapeutics Inc.

Named Competitors

• PARP Inhibitors and DNA Repair Therapeutics — Established DNA damage repair cancer therapies in clinical use
• Synthetic Lethal Drug Discovery Platforms — Competing platform-based precision oncology approaches

Recent Developments

• (January 2026) Shareholders approved XenoTherapeutics acquisition with 99.76% vote; company now operating as subsidiary
• (November 2025) Entered definitive agreement for acquisition by XenoTherapeutics at $1.82 per share plus contingent value rights
• (2025) Secured worldwide licensing deal with Debiopharm for lunresertib worth up to $257M in milestones
• (2025) Out-licensed discovery platforms to DCx Biotherapeutics for $1M upfront and 9.99% equity stake

Open the full interactive Repare Therapeutics Inc. report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.